Structure via PubChem · Public domain (PubChem)
tricaprylin
Sign in to saveAlso known as trioctanoylglyceride, Glycerol trioctanoin, Tricapryloylglycerol, Octanoic acid, 1,1',1''-(1,2,3-propanetriyl) ester, Glycerin tricaprylate, Tricaprylyl glycerin, TG(8:0/8:0/8:0), Glycerol tricaprylate
Axona was previously marketed as a medical food for the clinical dietary management of the impairment of metabolic processes associated with mild to moderate Alzheimer's disease. It is a proprietary formulation of fractionated palm kernel oil (caprylic triglyceride), a medium-chain triglyceride. Cericin, the company that makes Axona, states that during digestion, caprylic triglyceride is broken down into ketones, which provide an alternative energy source for the brain. Its use is based on the idea that the brain's ability to use its normal energy source, glucose, is impaired in Alzheimer's di
Chemical data
- Formula
- C27H50O6
- Molecular weight
- 470.7 g/mol
- IUPAC name
- 2,3-di(octanoyloxy)propyl octanoate
- SMILES
- CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC
- InChIKey
- VLPFTAMPNXLGLX-UHFFFAOYSA-N
- XLogP
- 8.9
- Polar surface area
- 78.9 Ų
- H-bond donors
- 0
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- memory impairment, developmental and epileptic encephalopathy, Alzheimer disease, migraine disorder
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 470.361
Show 4 more facts
- chemical formula
- C₂₇H₅₀O₆
- canonical SMILES
- CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC
- subject has role
- excipient
- Commons category
- Trioctanoin
Sources (2)
via Wikidata · CC0
~5 min read
Encyclopedic overview
7 sectionsContents
- Description
- Proposed mechanism of action of Axona
- Clinical trials
- Sales and marketing
- Criticism
- See also
- References
Axona was previously marketed as a medical food for the clinical dietary management of the impairment of metabolic processes associated with mild to moderate Alzheimer's disease. It is a proprietary formulation of fractionated palm kernel oil (caprylic triglyceride), a medium-chain triglyceride. Cericin, the company that makes Axona, states that during digestion, caprylic triglyceride is broken down into ketones, which provide an alternative energy source for the brain. Its use is based on the idea that the brain's ability to use its normal energy source, glucose, is impaired in Alzheimer's disease. Axona was first sold in March 2009.
In 2013, US Food and Drug Administration (FDA) determined Axona was misbranded because the product was labeled and marketed as a medical food but does not meet the statutory definition of a medical food. Axona has not been approved by the FDA as a drug to treat Alzheimer's and the efficacy of managing the health of Alzheimer's patients by use of this medical food has been questioned by experts in the field, including the Alzheimer's Association.
Excerpted from Wikipedia’s “tricaprylin” article, available under the CC BY-SA 4.0 licence.